

Surrey (East Surrey, Guildford & Waverley, North West Surrey, Surrey Downs, and Surrey Heath CCGs), Crawley CCG and Horsham & Mid-Sussex CCG

# Lurasidone Prescribing Pathway

The flow chart below describes the prescribing pathway and place in therapy of lurasidone to help in the management of schizophrenia of people once metabolic syndrome has been identified.

However, access to lurasidone will need to be authorised by the SABP Trust Chief Pharmacist to provide assurance of fidelity to the pathway.

# **Prescribing Pathway:** Diagnosis of Schizophrenia People living with schizophrenia who People living with schizophrenia who also have pre-existing Metabolic do not currently have Metabolic Syndrome/Diabetes (20%)\* Syndrome/Diabetes\* (80%) **Initial Treatment Initial Treatment** Try in succession as required: Any choice of medication 1. Aripiprazole (excluding lurasidone) 2. Amisulpride 3. Lurasidone 4. Other Cohort in whom Cohort in whom Metabolic Metabolic Syndrome/Diabetes Syndrome/Diabetes does not develop develops \*Success \*Success Criteria Met -Criteria not met - Try Continue Switch medication/try in Continue treatment alternative treatment succession as required: treatment 1. Aripiprazole 2. Amisulpride 3. Lurasidone \*Success Criteria not met -\*Success Criteria Met -Try alternative treatment Continue treatment

Date: Dec 2016

Review date: Dec 2019

Author: Surrey & Borders Partnership NHS Foundation Trust



Surrey (East Surrey, Guildford & Waverley, North West Surrey, Surrey Downs, and Surrey Heath CCGs), Crawley CCG and Horsham & Mid-Sussex CCG

## Metabolic Syndrome, Risk stratification and prescribing

Using the Lester tool we will identify people with pre-existing metabolic syndrome prior to treatment and those who go onto develop metabolic syndrome as a result of treatment.

## \*Criteria for metabolic syndrome

Three or more of the following:

**BMI** > 25kg/m2 (>23kg/m2 if south Asian or Chinese)

BP >140mg Hg Systolic

### Glucose

- FPG > 5.5mmol/l
- o RPG >11.1mmol/l
- HbA1c >42 mmol/mol (6%)


### **Blood Lipids**

Total Cholesterol/HDL ratio >10%

## \*Success criteria

Efficacy: maintenance or improvement in mental health symptoms seen at 4-6 weeks

Metabolic syndrome: Shift from red to amber or green zone (as per Lester Tool) for at least one of the following affected domains BMI/Glucose regulation/Blood Lipid after 3 months of treatment



Date: Dec 2016

Review date: Dec 2019

Author: Surrey & Borders Partnership NHS Foundation Trust